Exagen Inc. (XGN) 10-Year Financial Performance & Capital Metrics

XGN • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

AboutExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Show more

Revenue $56M +5.9%
EBITDA -$12M +42.4%
Net Income -$15M +36.2%
EPS (Diluted) -0.83 +38.1%
Gross Margin 59.51% +6.2%
EBITDA Margin -21.41% +45.6%
Operating Margin -24.51% +43.6%
Net Margin -27.17% +39.7%
ROE -93.78% -29.0%
ROIC -102.57% +26.0%
Debt/Equity 2.41 +135.6%
Interest Coverage -6.10 +37.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y33.67%

5Y6.62%

3Y4.83%

TTM14.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.13%

ROCE

10Y Avg-289.82%

5Y Avg-33.56%

3Y Avg-40.54%

Latest-35.78%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.66M	17.95M	26.81M	32.44M	40.39M	41.98M	48.3M	45.56M	52.55M	55.64M
Revenue Growth %	2.82%	0.54%	0.49%	0.21%	0.24%	0.04%	0.15%	-0.06%	0.15%	0.06%
Cost of Goods Sold+	6.88M	9.53M	14.14M	15.38M	18.81M	16.56M	20.59M	24.21M	23.09M	22.53M
COGS % of Revenue	0.59%	0.53%	0.53%	0.47%	0.47%	0.39%	0.43%	0.53%	0.44%	0.4%
Gross Profit+	4.78M	8.41M	12.67M	17.06M	21.58M	25.42M	27.71M	21.35M	29.46M	33.11M
Gross Margin %	0.41%	0.47%	0.47%	0.53%	0.53%	0.61%	0.57%	0.47%	0.56%	0.6%
Gross Profit Growth %	20.24%	0.76%	0.51%	0.35%	0.26%	0.18%	0.09%	-0.23%	0.38%	0.12%
Operating Expenses+	16.57M	19.07M	20.56M	21.94M	30.88M	40.6M	51.78M	67.4M	52.29M	46.75M
OpEx % of Revenue	1.42%	1.06%	0.77%	0.68%	0.76%	0.97%	1.07%	1.48%	1%	0.84%
Selling, General & Admin	15.07M	17.41M	18.82M	19.68M	28.7M	37.03M	44.54M	52.02M	47.43M	41.37M
SG&A % of Revenue	1.29%	0.97%	0.7%	0.61%	0.71%	0.88%	0.92%	1.14%	0.9%	0.74%
Research & Development	1.29M	1.37M	1.55M	2.13M	2.18M	3.57M	7.24M	9.88M	4.87M	5.38M
R&D % of Revenue	0.11%	0.08%	0.06%	0.07%	0.05%	0.09%	0.15%	0.22%	0.09%	0.1%
Other Operating Expenses	-497K	1.22M	186K	141K	0	0	0	5.51M	0	0
Operating Income+	-11.56M	-10.39M	-7.84M	-4.88M	-9.3M	-15.19M	-24.07M	-46.05M	-22.84M	-13.64M
Operating Margin %	-0.99%	-0.58%	-0.29%	-0.15%	-0.23%	-0.36%	-0.5%	-1.01%	-0.43%	-0.25%
Operating Income Growth %	-0.26%	0.1%	0.25%	0.38%	-0.91%	-0.63%	-0.58%	-0.91%	0.5%	0.4%
EBITDA+	-11M	-9.51M	-7.17M	-4.15M	-8.71M	-14.64M	-23.12M	-44.49M	-20.67M	-11.91M
EBITDA Margin %	-0.94%	-0.53%	-0.27%	-0.13%	-0.22%	-0.35%	-0.48%	-0.98%	-0.39%	-0.21%
EBITDA Growth %	-0.27%	0.14%	0.25%	0.42%	-1.1%	-0.68%	-0.58%	-0.92%	0.54%	0.42%
D&A (Non-Cash Add-back)	558K	879K	670K	731K	591K	546K	948K	1.56M	2.17M	1.72M
EBIT	-12.05M	-14.43M	-23.23M	-5.09M	-8.52M	-14.2M	-24.05M	-45.22M	-21.32M	-12.87M
Net Interest Income+	-2.94M	-4.5M	-2.9M	-2.87M	-3.49M	-2.56M	-2.61M	-1.62M	-819K	-1.47M
Interest Income	0	0	45K	0	0	0	16K	830K	1.52M	767K
Interest Expense	2.94M	4.5M	2.95M	2.87M	3.49M	2.56M	2.63M	2.45M	2.33M	2.23M
Other Income/Expense	-3.44M	-8.54M	-18.34M	-3.07M	-2.71M	-1.58M	-2.61M	-1.62M	-819K	-1.47M
Pretax Income+	-14.99M	-18.93M	-26.18M	-7.95M	-12.01M	-16.77M	-26.68M	-47.67M	-23.66M	-15.1M
Pretax Margin %	-1.29%	-1.05%	-0.98%	-0.25%	-0.3%	-0.4%	-0.55%	-1.05%	-0.45%	-0.27%
Income Tax+	-13K	253K	-549K	58K	25K	-79K	175K	-282K	33K	12K
Effective Tax Rate %	1%	1.01%	0.98%	1.01%	1%	1%	1.01%	0.99%	1%	1%
Net Income+	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Net Margin %	-1.28%	-1.07%	-0.96%	-0.25%	-0.3%	-0.4%	-0.56%	-1.04%	-0.45%	-0.27%
Net Income Growth %	-0.11%	-0.28%	-0.34%	0.69%	-0.5%	-0.39%	-0.61%	-0.76%	0.5%	0.36%
Net Income (Continuing)	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-265.79	-305.48	-406.81	-127.16	-0.96	-1.32	-1.68	-2.77	-1.34	-0.83
EPS Growth %	-0.06%	-0.15%	-0.33%	0.69%	0.99%	-0.38%	-0.27%	-0.65%	0.52%	0.38%
EPS (Basic)	-265.79	-305.48	-406.81	-127.16	-0.96	-1.32	-1.68	-2.77	-1.34	-0.83
Diluted Shares Outstanding	56.36K	62.8K	63.01K	63.01K	12.56M	12.65M	15.97M	17.08M	17.68M	18.2M
Basic Shares Outstanding	56.36K	62.8K	63.01K	63.01K	12.56M	12.65M	15.97M	17.08M	17.68M	18.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.08M	3.87M	13.26M	21.31M	81.25M	70.52M	112.73M	72.61M	47.84M	36.45M
Cash & Short-Term Investments	4.61M	2.51M	11.24M	13.16M	72.08M	57.45M	99.44M	62.39M	36.49M	22.04M
Cash Only	4.61M	2.51M	11.24M	13.16M	72.08M	57.45M	99.44M	62.39M	36.49M	22.04M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	604K	5.95M	5.71M	8.91M	9.65M	6.08M	6.55M	7.83M
Days Sales Outstanding	-	-	8.22	66.97	51.65	77.48	72.96	48.68	45.5	51.4
Inventory	0	0	544K	1.02M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	14.05	24.26	-	-	-	-	-	-
Other Current Assets	349K	804K	871K	1.17M	0	0	490K	236K	1.93M	859K
Total Non-Current Assets+	12.07M	10.76M	7.13M	7.58M	7.06M	7.86M	10.71M	13.61M	9.1M	8.23M
Property, Plant & Equipment	1.54M	1.59M	1.34M	1.57M	1.38M	2.1M	4.77M	13.08M	8.49M	7.68M
Fixed Asset Turnover	7.58x	11.26x	19.96x	20.72x	29.27x	19.97x	10.12x	3.48x	6.19x	7.24x
Goodwill	5.51M	5.51M	5.51M	5.51M	5.51M	5.51M	5.51M	0	0	0
Intangible Assets	805K	514K	141K	0	0	0	0	0	0	0
Long-Term Investments	0	0	100K	100K	0	0	0	0	0	0
Other Non-Current Assets	2.5M	3.15M	-348K	-24K	174K	250K	433K	528K	616K	550K
Total Assets+	17.15M	14.63M	20.39M	28.89M	88.31M	78.38M	123.44M	86.22M	56.94M	44.69M
Asset Turnover	0.68x	1.23x	1.31x	1.12x	0.46x	0.54x	0.39x	0.53x	0.92x	1.25x
Asset Growth %	0.04%	-0.15%	0.39%	0.42%	2.06%	-0.11%	0.58%	-0.3%	-0.34%	-0.22%
Total Current Liabilities+	26.26M	34.92M	4.99M	8.95M	5.89M	8.77M	9.32M	9.62M	11.9M	13.51M
Accounts Payable	1.84M	2.18M	1.77M	1.28M	1.48M	3.01M	2.49M	3.05M	3.13M	4.14M
Days Payables Outstanding	97.49	83.54	45.75	30.36	28.64	66.44	44.18	45.92	49.49	67.02
Short-Term Debt	18.39M	25.86M	0	0	0	0	0	190K	264K	423K
Deferred Revenue (Current)	1000K	1000K	0	1000K	0	0	0	0	0	0
Other Current Liabilities	1.83M	3.18M	1.22M	4.11M	0	0	0	445K	0	0
Current Ratio	0.19x	0.11x	2.66x	2.38x	13.78x	8.04x	12.10x	7.55x	4.02x	2.70x
Quick Ratio	0.19x	0.11x	2.55x	2.27x	13.78x	8.04x	12.10x	7.55x	4.02x	2.70x
Cash Conversion Cycle	-	-	-23.48	60.87	-	-	-	-	-	-
Total Non-Current Liabilities+	4.94M	1.89M	20.04M	26.67M	26.76M	27.77M	29.19M	34.14M	22.35M	21.64M
Long-Term Debt	1.46M	0	18.81M	24.62M	25.85M	26.66M	27.48M	28.78M	19.23M	19.82M
Capital Lease Obligations	265K	0	81K	279K	0	0	0	4.49M	2.76M	1.66M
Deferred Tax Liabilities	0	416K	214K	245K	264K	158K	306K	0	0	0
Other Non-Current Liabilities	1.76M	1.48M	-644K	-1.23M	638K	948K	1.41M	867K	357K	157K
Total Liabilities	31.2M	36.81M	25.03M	35.62M	32.65M	36.54M	38.51M	43.76M	34.25M	35.15M
Total Debt+	18.52M	25.9M	18.84M	24.7M	26.09M	26.97M	28.07M	35.2M	23.23M	23M
Net Debt	13.91M	23.39M	7.59M	11.53M	-45.99M	-30.48M	-71.38M	-27.19M	-13.26M	969K
Debt / Equity	-	-	-	-	0.47x	0.64x	0.33x	0.83x	1.02x	2.41x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.93x	-2.31x	-2.66x	-1.70x	-2.66x	-5.92x	-9.17x	-18.81x	-9.78x	-6.10x
Total Equity+	-14.06M	-22.18M	-4.64M	-6.73M	55.66M	41.84M	84.94M	42.46M	22.69M	9.54M
Equity Growth %	-32.17%	-0.58%	0.79%	-0.45%	9.27%	-0.25%	1.03%	-0.5%	-0.47%	-0.58%
Book Value per Share	-249.38	-353.27	-73.61	-106.88	4.43	3.31	5.32	2.49	1.28	0.52
Total Shareholders' Equity	-14.06M	-22.18M	-4.64M	-6.73M	55.66M	41.84M	84.94M	42.46M	22.69M	9.54M
Common Stock	12K	12K	12K	12K	13K	13K	16K	17K	17K	18K
Retained Earnings	-89.27M	-108.45M	-147.64M	-152.56M	-164.6M	-181.29M	-208.14M	-255.53M	-279.22M	-294.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.63M	-2.18M	-2.18M	-1.82M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.77M	-11.9M	-10.97M	-9.3M	-9.71M	-14.08M	-20.27M	-32.14M	-14.46M	-13.28M
Operating CF Margin %	-0.92%	-0.66%	-0.41%	-0.29%	-0.24%	-0.34%	-0.42%	-0.71%	-0.28%	-0.24%
Operating CF Growth %	-0.57%	-0.1%	0.08%	0.15%	-0.04%	-0.45%	-0.44%	-0.59%	0.55%	0.08%
Net Income	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Depreciation & Amortization	558K	879K	670K	731K	591K	546K	948K	1.56M	2.17M	1.72M
Stock-Based Compensation	279K	287K	187K	114K	572K	2.69M	4.73M	4.7M	3.62M	1.76M
Deferred Taxes	-14K	251K	-554K	31K	-247K	-106K	148K	-306K	0	0
Other Non-Cash Items	1.71M	6.76M	16.38M	1.43M	1.24M	805K	819K	7.62M	3.12M	1.43M
Working Capital Changes	1.68M	-896K	-2.02M	-3.59M	174K	-1.34M	-61K	1.67M	325K	-3.08M
Change in Receivables	55K	0	-198K	-2.26M	237K	-3.19M	-744K	3.58M	-474K	-1.28M
Change in Inventory	261K	0	436K	-497K	-567K	0	0	0	0	0
Change in Payables	1.4M	77K	44K	-824K	528K	986K	-655K	901K	67K	308K
Cash from Investing+	-649K	-800K	-510K	-199K	-103K	-455K	-2.42M	-4.32M	-804K	-515K
Capital Expenditures	-649K	-805K	-567K	-199K	-403K	-455K	-2.37M	-4.32M	-828K	-515K
CapEx % of Revenue	0.06%	0.04%	0.02%	0.01%	0.01%	0.01%	0.05%	0.09%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	5K	57K	0	0	0	-50K	0	24K	0
Cash from Financing+	8.28M	10.61M	19.16M	11.42M	68.73M	-97K	64.68M	-489K	-10.63M	-663K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-6.74M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-635K	-147K	14.64M	6.47M	6.74M	-21K	-3.94M	-239K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.42M	-12.71M	-11.54M	-9.5M	-10.11M	-14.54M	-22.64M	-36.46M	-15.29M	-13.79M
FCF Margin %	-0.98%	-0.71%	-0.43%	-0.29%	-0.25%	-0.35%	-0.47%	-0.8%	-0.29%	-0.25%
FCF Growth %	-0.62%	-0.11%	0.09%	0.18%	-0.06%	-0.44%	-0.56%	-0.61%	0.58%	0.1%
FCF per Share	-202.65	-202.35	-183.08	-150.78	-0.81	-1.15	-1.42	-2.13	-0.86	-0.76
FCF Conversion (FCF/Net Income)	0.72x	0.62x	0.43x	1.16x	0.81x	0.84x	0.75x	0.68x	0.61x	0.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-49.21%	-34.23%	-42.36%	-74.39%	-72.72%	-93.78%
Return on Invested Capital (ROIC)	-1172.01%	-1461.73%	-282.07%	-94.37%	-96.42%	-108.34%	-144.88%	-239.61%	-138.67%	-102.57%
Gross Margin	40.97%	46.88%	47.26%	52.59%	53.43%	60.55%	57.37%	46.86%	56.06%	59.51%
Net Margin	-128.45%	-106.89%	-95.61%	-24.7%	-29.81%	-39.75%	-55.59%	-104%	-45.08%	-27.17%
Debt / Equity	-	-	-	-	0.47x	0.64x	0.33x	0.83x	1.02x	2.41x
Interest Coverage	-3.93x	-2.31x	-2.66x	-1.70x	-2.66x	-5.92x	-9.17x	-18.81x	-9.78x	-6.10x
FCF Conversion	0.72x	0.62x	0.43x	1.16x	0.81x	0.84x	0.75x	0.68x	0.61x	0.88x
Revenue Growth	281.77%	53.87%	49.38%	21.01%	24.5%	3.93%	15.07%	-5.66%	15.33%	5.89%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Shipping and Handling	1.4M	1.4M	2.1M	2.7M	2.5M	3.1M
Shipping and Handling Growth	-	0.00%	50.00%	28.57%	-7.41%	24.00%

Frequently Asked Questions

Growth & Financials

Exagen Inc. (XGN) reported $63.6M in revenue for fiscal year 2024. This represents a 6768% increase from $0.9M in 2012.

Exagen Inc. (XGN) grew revenue by 5.9% over the past year. This is steady growth.

Exagen Inc. (XGN) reported a net loss of $19.0M for fiscal year 2024.

Dividend & Returns

Exagen Inc. (XGN) has a return on equity (ROE) of -93.8%. Negative ROE indicates the company is unprofitable.

Exagen Inc. (XGN) had negative free cash flow of $11.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Exagen Inc. (XGN) 10-Year Financial Performance & Capital Metrics

XGN • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesSpecialized Testing Laboratories

Revenue $56M +5.9%
EBITDA -$12M +42.4%
Net Income -$15M +36.2%
EPS (Diluted) -0.83 +38.1%
Gross Margin 59.51% +6.2%
EBITDA Margin -21.41% +45.6%
Operating Margin -24.51% +43.6%
Net Margin -27.17% +39.7%
ROE -93.78% -29.0%
ROIC -102.57% +26.0%
Debt/Equity 2.41 +135.6%
Interest Coverage -6.10 +37.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y33.67%

5Y6.62%

3Y4.83%

TTM14.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.13%

ROCE

10Y Avg-289.82%

5Y Avg-33.56%

3Y Avg-40.54%

Latest-35.78%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.66M	17.95M	26.81M	32.44M	40.39M	41.98M	48.3M	45.56M	52.55M	55.64M
Revenue Growth %	2.82%	0.54%	0.49%	0.21%	0.24%	0.04%	0.15%	-0.06%	0.15%	0.06%
Cost of Goods Sold+	6.88M	9.53M	14.14M	15.38M	18.81M	16.56M	20.59M	24.21M	23.09M	22.53M
COGS % of Revenue	0.59%	0.53%	0.53%	0.47%	0.47%	0.39%	0.43%	0.53%	0.44%	0.4%
Gross Profit+	4.78M	8.41M	12.67M	17.06M	21.58M	25.42M	27.71M	21.35M	29.46M	33.11M
Gross Margin %	0.41%	0.47%	0.47%	0.53%	0.53%	0.61%	0.57%	0.47%	0.56%	0.6%
Gross Profit Growth %	20.24%	0.76%	0.51%	0.35%	0.26%	0.18%	0.09%	-0.23%	0.38%	0.12%
Operating Expenses+	16.57M	19.07M	20.56M	21.94M	30.88M	40.6M	51.78M	67.4M	52.29M	46.75M
OpEx % of Revenue	1.42%	1.06%	0.77%	0.68%	0.76%	0.97%	1.07%	1.48%	1%	0.84%
Selling, General & Admin	15.07M	17.41M	18.82M	19.68M	28.7M	37.03M	44.54M	52.02M	47.43M	41.37M
SG&A % of Revenue	1.29%	0.97%	0.7%	0.61%	0.71%	0.88%	0.92%	1.14%	0.9%	0.74%
Research & Development	1.29M	1.37M	1.55M	2.13M	2.18M	3.57M	7.24M	9.88M	4.87M	5.38M
R&D % of Revenue	0.11%	0.08%	0.06%	0.07%	0.05%	0.09%	0.15%	0.22%	0.09%	0.1%
Other Operating Expenses	-497K	1.22M	186K	141K	0	0	0	5.51M	0	0
Operating Income+	-11.56M	-10.39M	-7.84M	-4.88M	-9.3M	-15.19M	-24.07M	-46.05M	-22.84M	-13.64M
Operating Margin %	-0.99%	-0.58%	-0.29%	-0.15%	-0.23%	-0.36%	-0.5%	-1.01%	-0.43%	-0.25%
Operating Income Growth %	-0.26%	0.1%	0.25%	0.38%	-0.91%	-0.63%	-0.58%	-0.91%	0.5%	0.4%
EBITDA+	-11M	-9.51M	-7.17M	-4.15M	-8.71M	-14.64M	-23.12M	-44.49M	-20.67M	-11.91M
EBITDA Margin %	-0.94%	-0.53%	-0.27%	-0.13%	-0.22%	-0.35%	-0.48%	-0.98%	-0.39%	-0.21%
EBITDA Growth %	-0.27%	0.14%	0.25%	0.42%	-1.1%	-0.68%	-0.58%	-0.92%	0.54%	0.42%
D&A (Non-Cash Add-back)	558K	879K	670K	731K	591K	546K	948K	1.56M	2.17M	1.72M
EBIT	-12.05M	-14.43M	-23.23M	-5.09M	-8.52M	-14.2M	-24.05M	-45.22M	-21.32M	-12.87M
Net Interest Income+	-2.94M	-4.5M	-2.9M	-2.87M	-3.49M	-2.56M	-2.61M	-1.62M	-819K	-1.47M
Interest Income	0	0	45K	0	0	0	16K	830K	1.52M	767K
Interest Expense	2.94M	4.5M	2.95M	2.87M	3.49M	2.56M	2.63M	2.45M	2.33M	2.23M
Other Income/Expense	-3.44M	-8.54M	-18.34M	-3.07M	-2.71M	-1.58M	-2.61M	-1.62M	-819K	-1.47M
Pretax Income+	-14.99M	-18.93M	-26.18M	-7.95M	-12.01M	-16.77M	-26.68M	-47.67M	-23.66M	-15.1M
Pretax Margin %	-1.29%	-1.05%	-0.98%	-0.25%	-0.3%	-0.4%	-0.55%	-1.05%	-0.45%	-0.27%
Income Tax+	-13K	253K	-549K	58K	25K	-79K	175K	-282K	33K	12K
Effective Tax Rate %	1%	1.01%	0.98%	1.01%	1%	1%	1.01%	0.99%	1%	1%
Net Income+	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Net Margin %	-1.28%	-1.07%	-0.96%	-0.25%	-0.3%	-0.4%	-0.56%	-1.04%	-0.45%	-0.27%
Net Income Growth %	-0.11%	-0.28%	-0.34%	0.69%	-0.5%	-0.39%	-0.61%	-0.76%	0.5%	0.36%
Net Income (Continuing)	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-265.79	-305.48	-406.81	-127.16	-0.96	-1.32	-1.68	-2.77	-1.34	-0.83
EPS Growth %	-0.06%	-0.15%	-0.33%	0.69%	0.99%	-0.38%	-0.27%	-0.65%	0.52%	0.38%
EPS (Basic)	-265.79	-305.48	-406.81	-127.16	-0.96	-1.32	-1.68	-2.77	-1.34	-0.83
Diluted Shares Outstanding	56.36K	62.8K	63.01K	63.01K	12.56M	12.65M	15.97M	17.08M	17.68M	18.2M
Basic Shares Outstanding	56.36K	62.8K	63.01K	63.01K	12.56M	12.65M	15.97M	17.08M	17.68M	18.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.08M	3.87M	13.26M	21.31M	81.25M	70.52M	112.73M	72.61M	47.84M	36.45M
Cash & Short-Term Investments	4.61M	2.51M	11.24M	13.16M	72.08M	57.45M	99.44M	62.39M	36.49M	22.04M
Cash Only	4.61M	2.51M	11.24M	13.16M	72.08M	57.45M	99.44M	62.39M	36.49M	22.04M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	604K	5.95M	5.71M	8.91M	9.65M	6.08M	6.55M	7.83M
Days Sales Outstanding	-	-	8.22	66.97	51.65	77.48	72.96	48.68	45.5	51.4
Inventory	0	0	544K	1.02M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	14.05	24.26	-	-	-	-	-	-
Other Current Assets	349K	804K	871K	1.17M	0	0	490K	236K	1.93M	859K
Total Non-Current Assets+	12.07M	10.76M	7.13M	7.58M	7.06M	7.86M	10.71M	13.61M	9.1M	8.23M
Property, Plant & Equipment	1.54M	1.59M	1.34M	1.57M	1.38M	2.1M	4.77M	13.08M	8.49M	7.68M
Fixed Asset Turnover	7.58x	11.26x	19.96x	20.72x	29.27x	19.97x	10.12x	3.48x	6.19x	7.24x
Goodwill	5.51M	5.51M	5.51M	5.51M	5.51M	5.51M	5.51M	0	0	0
Intangible Assets	805K	514K	141K	0	0	0	0	0	0	0
Long-Term Investments	0	0	100K	100K	0	0	0	0	0	0
Other Non-Current Assets	2.5M	3.15M	-348K	-24K	174K	250K	433K	528K	616K	550K
Total Assets+	17.15M	14.63M	20.39M	28.89M	88.31M	78.38M	123.44M	86.22M	56.94M	44.69M
Asset Turnover	0.68x	1.23x	1.31x	1.12x	0.46x	0.54x	0.39x	0.53x	0.92x	1.25x
Asset Growth %	0.04%	-0.15%	0.39%	0.42%	2.06%	-0.11%	0.58%	-0.3%	-0.34%	-0.22%
Total Current Liabilities+	26.26M	34.92M	4.99M	8.95M	5.89M	8.77M	9.32M	9.62M	11.9M	13.51M
Accounts Payable	1.84M	2.18M	1.77M	1.28M	1.48M	3.01M	2.49M	3.05M	3.13M	4.14M
Days Payables Outstanding	97.49	83.54	45.75	30.36	28.64	66.44	44.18	45.92	49.49	67.02
Short-Term Debt	18.39M	25.86M	0	0	0	0	0	190K	264K	423K
Deferred Revenue (Current)	1000K	1000K	0	1000K	0	0	0	0	0	0
Other Current Liabilities	1.83M	3.18M	1.22M	4.11M	0	0	0	445K	0	0
Current Ratio	0.19x	0.11x	2.66x	2.38x	13.78x	8.04x	12.10x	7.55x	4.02x	2.70x
Quick Ratio	0.19x	0.11x	2.55x	2.27x	13.78x	8.04x	12.10x	7.55x	4.02x	2.70x
Cash Conversion Cycle	-	-	-23.48	60.87	-	-	-	-	-	-
Total Non-Current Liabilities+	4.94M	1.89M	20.04M	26.67M	26.76M	27.77M	29.19M	34.14M	22.35M	21.64M
Long-Term Debt	1.46M	0	18.81M	24.62M	25.85M	26.66M	27.48M	28.78M	19.23M	19.82M
Capital Lease Obligations	265K	0	81K	279K	0	0	0	4.49M	2.76M	1.66M
Deferred Tax Liabilities	0	416K	214K	245K	264K	158K	306K	0	0	0
Other Non-Current Liabilities	1.76M	1.48M	-644K	-1.23M	638K	948K	1.41M	867K	357K	157K
Total Liabilities	31.2M	36.81M	25.03M	35.62M	32.65M	36.54M	38.51M	43.76M	34.25M	35.15M
Total Debt+	18.52M	25.9M	18.84M	24.7M	26.09M	26.97M	28.07M	35.2M	23.23M	23M
Net Debt	13.91M	23.39M	7.59M	11.53M	-45.99M	-30.48M	-71.38M	-27.19M	-13.26M	969K
Debt / Equity	-	-	-	-	0.47x	0.64x	0.33x	0.83x	1.02x	2.41x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.93x	-2.31x	-2.66x	-1.70x	-2.66x	-5.92x	-9.17x	-18.81x	-9.78x	-6.10x
Total Equity+	-14.06M	-22.18M	-4.64M	-6.73M	55.66M	41.84M	84.94M	42.46M	22.69M	9.54M
Equity Growth %	-32.17%	-0.58%	0.79%	-0.45%	9.27%	-0.25%	1.03%	-0.5%	-0.47%	-0.58%
Book Value per Share	-249.38	-353.27	-73.61	-106.88	4.43	3.31	5.32	2.49	1.28	0.52
Total Shareholders' Equity	-14.06M	-22.18M	-4.64M	-6.73M	55.66M	41.84M	84.94M	42.46M	22.69M	9.54M
Common Stock	12K	12K	12K	12K	13K	13K	16K	17K	17K	18K
Retained Earnings	-89.27M	-108.45M	-147.64M	-152.56M	-164.6M	-181.29M	-208.14M	-255.53M	-279.22M	-294.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.63M	-2.18M	-2.18M	-1.82M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.77M	-11.9M	-10.97M	-9.3M	-9.71M	-14.08M	-20.27M	-32.14M	-14.46M	-13.28M
Operating CF Margin %	-0.92%	-0.66%	-0.41%	-0.29%	-0.24%	-0.34%	-0.42%	-0.71%	-0.28%	-0.24%
Operating CF Growth %	-0.57%	-0.1%	0.08%	0.15%	-0.04%	-0.45%	-0.44%	-0.59%	0.55%	0.08%
Net Income	-14.98M	-19.18M	-25.63M	-8.01M	-12.04M	-16.69M	-26.85M	-47.39M	-23.69M	-15.12M
Depreciation & Amortization	558K	879K	670K	731K	591K	546K	948K	1.56M	2.17M	1.72M
Stock-Based Compensation	279K	287K	187K	114K	572K	2.69M	4.73M	4.7M	3.62M	1.76M
Deferred Taxes	-14K	251K	-554K	31K	-247K	-106K	148K	-306K	0	0
Other Non-Cash Items	1.71M	6.76M	16.38M	1.43M	1.24M	805K	819K	7.62M	3.12M	1.43M
Working Capital Changes	1.68M	-896K	-2.02M	-3.59M	174K	-1.34M	-61K	1.67M	325K	-3.08M
Change in Receivables	55K	0	-198K	-2.26M	237K	-3.19M	-744K	3.58M	-474K	-1.28M
Change in Inventory	261K	0	436K	-497K	-567K	0	0	0	0	0
Change in Payables	1.4M	77K	44K	-824K	528K	986K	-655K	901K	67K	308K
Cash from Investing+	-649K	-800K	-510K	-199K	-103K	-455K	-2.42M	-4.32M	-804K	-515K
Capital Expenditures	-649K	-805K	-567K	-199K	-403K	-455K	-2.37M	-4.32M	-828K	-515K
CapEx % of Revenue	0.06%	0.04%	0.02%	0.01%	0.01%	0.01%	0.05%	0.09%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	5K	57K	0	0	0	-50K	0	24K	0
Cash from Financing+	8.28M	10.61M	19.16M	11.42M	68.73M	-97K	64.68M	-489K	-10.63M	-663K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-6.74M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-635K	-147K	14.64M	6.47M	6.74M	-21K	-3.94M	-239K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.42M	-12.71M	-11.54M	-9.5M	-10.11M	-14.54M	-22.64M	-36.46M	-15.29M	-13.79M
FCF Margin %	-0.98%	-0.71%	-0.43%	-0.29%	-0.25%	-0.35%	-0.47%	-0.8%	-0.29%	-0.25%
FCF Growth %	-0.62%	-0.11%	0.09%	0.18%	-0.06%	-0.44%	-0.56%	-0.61%	0.58%	0.1%
FCF per Share	-202.65	-202.35	-183.08	-150.78	-0.81	-1.15	-1.42	-2.13	-0.86	-0.76
FCF Conversion (FCF/Net Income)	0.72x	0.62x	0.43x	1.16x	0.81x	0.84x	0.75x	0.68x	0.61x	0.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-49.21%	-34.23%	-42.36%	-74.39%	-72.72%	-93.78%
Return on Invested Capital (ROIC)	-1172.01%	-1461.73%	-282.07%	-94.37%	-96.42%	-108.34%	-144.88%	-239.61%	-138.67%	-102.57%
Gross Margin	40.97%	46.88%	47.26%	52.59%	53.43%	60.55%	57.37%	46.86%	56.06%	59.51%
Net Margin	-128.45%	-106.89%	-95.61%	-24.7%	-29.81%	-39.75%	-55.59%	-104%	-45.08%	-27.17%
Debt / Equity	-	-	-	-	0.47x	0.64x	0.33x	0.83x	1.02x	2.41x
Interest Coverage	-3.93x	-2.31x	-2.66x	-1.70x	-2.66x	-5.92x	-9.17x	-18.81x	-9.78x	-6.10x
FCF Conversion	0.72x	0.62x	0.43x	1.16x	0.81x	0.84x	0.75x	0.68x	0.61x	0.88x
Revenue Growth	281.77%	53.87%	49.38%	21.01%	24.5%	3.93%	15.07%	-5.66%	15.33%	5.89%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Shipping and Handling	1.4M	1.4M	2.1M	2.7M	2.5M	3.1M
Shipping and Handling Growth	-	0.00%	50.00%	28.57%	-7.41%	24.00%

Frequently Asked Questions

Growth & Financials

Exagen Inc. (XGN) reported $63.6M in revenue for fiscal year 2024. This represents a 6768% increase from $0.9M in 2012.

Exagen Inc. (XGN) grew revenue by 5.9% over the past year. This is steady growth.

Exagen Inc. (XGN) reported a net loss of $19.0M for fiscal year 2024.

Dividend & Returns

Exagen Inc. (XGN) has a return on equity (ROE) of -93.8%. Negative ROE indicates the company is unprofitable.

Exagen Inc. (XGN) had negative free cash flow of $11.0M in fiscal year 2024, likely due to heavy capital investments.